Abstract

Despite its widespread use, the clinical utility of 5-fluorouracil (5FU) is limited by systemic toxicity, poor selectivity, and drug resistance in aggressive cancers, such as the Triple Negative Breast Cancer (TNBC). This study investigates a polymeric hybrid nanoparticle (NP) system co-delivering 5FU with Santalum album EO (SAEO), a natural product rich in α- santalol, to enhance therapeutic efficacy and achieve controlled release for TNBC Treatment. Chitosan-based nanoparticles were developed using ionic gelation to encapsulate 5FU and SAEO, followed by the Design of Experiments (DOE) optimization. The optimized nanoparticles exhibited a mean size of 363.8 ± 11.68 nm, a zeta potential (ZP) of 12.7 ± 0.57 mV, and demonstrated a high encapsulation efficiency (EE%) of 88.60 ± 0.73.% along with a loading capacity (LC%) of 17.0 ± 0.08%. Fourier transform infrared spectroscopy (FTIR), and thermogravimetric analysis (TGA) confirmed successfully incorporating 5- 5FU and SAEO into the system. The nanoparticles displayed controlled and sustained drug release characteristics compared to free 5FU. The combinatorial formulation of 5FU/SAEO@CS-NP exhibited superior anti-cancer activity, with IC50 values recorded at 12.1 ± 0.20 μg/mL for MDA-MB-231 cells and 8.7 ± 1.43 μg/mL for MCF-7 cells. The free SAEO and SAEO@CS-NP formulations demonstrated significant selectivity toward the MDA-MB-231 cells, and at the prospective IC50, normal cells are viable by more than 80%.

School

School of Sciences and Engineering

Department

Chemistry Department

Degree Name

MS in Chemistry

Graduation Date

Winter 1-31-2025

Submission Date

1-28-2025

First Advisor

Dr. Wael Mamdouh

Committee Member 1

Dr. Hatem Talima

Committee Member 2

Dr. Maha Nasr

Extent

140 p.

Document Type

Master's Thesis

Institutional Review Board (IRB) Approval

Not necessary for this item

Download

Available for download on Thursday, January 28, 2027

Included in

Life Sciences Commons

Share

COinS